Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial

BACKGROUND: The ICON8 study reported no significant improvement in progression-free survival (a primary endpoint) with weekly chemotherapy compared with standard 3-weekly treatment among patients with epithelial ovarian cancer. All ICON8 patients were eligible to take part in the accompanying health...

Descripción completa

Detalles Bibliográficos
Autores principales: Blagden, Sarah P, Cook, Adrian D, Poole, Christopher, Howells, Lesley, McNeish, Ian A, Dean, Andrew, Kim, Jae-Weon, O'Donnell, Dearbhaile M, Hook, Jane, James, Elizabeth C, White, Ian R, Perren, Timothy, Lord, Rosemary, Dark, Graham, Earl, Helena M, Hall, Marcia, Kaplan, Richard, Ledermann, Jonathan A, Clamp, Andrew R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lancet Pub. Group 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327508/
https://www.ncbi.nlm.nih.gov/pubmed/32615110
http://dx.doi.org/10.1016/S1470-2045(20)30218-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327508/
https://www.ncbi.nlm.nih.gov/pubmed/32615110
http://dx.doi.org/10.1016/S1470-2045(20)30218-7

Ejemplares similares